文献速递临床试验与 GCP基础与转化研究

重组人五聚蛋白2对特发性肺纤维化患者用力肺活量变化的影响:一项随机临床试验

Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2018-01-01

这项2期随机双盲安慰剂对照试验在7国18个中心纳入117例特发性肺纤维化患者,评估重组人五聚蛋白2(10 mg/kg 静脉每4周)与安慰剂对第28周用力肺活量占预计值百分比变化的影响。

要点

  • 重组人五聚蛋白2可能减缓IPF患者28周内肺功能下降。
  • 6分钟步行距离变化治疗组优于安慰剂组。
  • 肺容积、HRCT定量特征及Dlco未见显著组间差异。

核心结论

  • 在初步研究中,与安慰剂相比,重组人五聚蛋白2使特发性肺纤维化患者28周内肺功能下降更慢。
  • 需要进一步研究更全面评估疗效和安全性。

研究设计与样本

  • 2期、随机、双盲、安慰剂对照试验,在7个国家18个中心进行。
  • 纳入117例符合条件的特发性肺纤维化患者,年龄40-80岁,FVC占预计值≥50%且≤90%,FEV1/FVC>0.70,Dlco占预计值≥25%且≤90%,6分钟步行距离≥150米。
  • 研究期为2015年8月至2017年5月。
  • 患者随机接受重组人五聚蛋白2(10 mg/kg静脉每4周,n=77)或安慰剂(n=39)治疗24周,按是否合并IPF治疗分层。
  • 117例随机患者中116例至少接受1剂研究药物(平均年龄68.6岁;81.0%男性;平均IPF诊断时间3.8年),111例(95.7%)完成研究。

主要发现

  • 总肺容积差值93.5 mL(90%CI -27.7至214.7),无显著治疗差异。
  • HRCT定量肺实质特征:正常肺容积差值-1.2%(90%CI -4.4至1.9),间质性肺异常差值1.1%(90%CI -2.2至4.3),均无显著差异。
  • Dlco差值-0.4(90%CI -2.6至1.7),无显著治疗差异。

关键数值与推荐

  • 主要终点为第28周FVC占预计值百分比较基线的最小二乘均值变化,最小临床重要差异为下降2%-6%。
  • 6分钟步行距离最小临床重要差异为24-45 m。
  • 重组人五聚蛋白2给药方案为10 mg/kg静脉每4周,治疗24周。

临床怎么用

  • 对于符合条件的特发性肺纤维化患者,重组人五聚蛋白2可能作为减缓肺功能下降的潜在治疗选择,但需进一步研究确认。
  • 治疗期间应监测常见不良事件如咳嗽、疲劳和鼻咽炎。

局限性

  • 本研究为初步研究,样本量有限(N=117),需更大规模研究评估疗效和安全性。
  • 研究仅观察28周,长期效果未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with poor prognosis. Approved therapies do not halt disease progression. OBJECTIVE: To determine the effect of recombinant human pentraxin 2 vs placebo on change from baseline to week 28 in mean forced vital capacity (FVC) percentage of predicted value. DESIGN, SETTING, AND PARTICIPANTS: Phase 2, randomized, double-blind, placebo-controlled trial conducted at 18 sites in 7 countries of eligible patients with IPF (N = 117; aged 40-80 years; FVC ≥50% and ≤90% predicted; ratio of forced expiratory volume in the first second/FVC >0.70; diffusing capacity for carbon monoxide [Dlco] ≥25% and ≤90% predicted; and distance of ≥150 m on the 6-minute walk test). Study period was August 2015-May 2017. INTERVENTIONS: Patients were randomized to receive either recombinant human pentraxin 2 (10 mg/kg intravenous every 4 weeks, n = 77) or placebo (n = 39) for 24 weeks, and stratified by concurrent IPF treatment status. MAIN OUTCOMES AND MEASURES: The primary end point was the least-squares mean change in FVC percentage of predicted value from baseline to week 28 (minimal clinically important difference, decline of 2%-6%). Secondary end points included mean change in lung volumes (total, normal, and interstitial lung abnormalities) on high-resolution computed tomography (HRCT) and 6-minute walk distance (minimal clinically important difference, 24-45 m). RESULTS: Of 117 randomized patients, 116 received at least 1 dose of study drug (mean age, 68.6 years; 81.0% men; mean time since IPF diagnosis, 3.8 years), and 111 (95.7%) completed the study. The least-squares mean change in FVC percentage of predicted value from baseline to week 28 in patients treated with recombinant human pentraxin 2 was -2.5 vs -4.8 for those in the placebo group (difference, +2.3 [90% CI, 1.1 to 3.5]; P = .001). No significant treatment differences were observed in total lung volume (difference, 93.5 mL [90% CI, -27.7 to 214.7]), quantitative parenchymal features on HRCT (normal lung volume difference, -1.2% [90% CI, -4.4 to 1.9]; interstitial lung abnormalities difference, 1.1% [90% CI, -2.2 to 4.3]), or measurement of Dlco (difference, -0.4 [90% CI, -2.6 to 1.7]). The change in 6-minute walk distance was -0.5 m for patients treated with recombinant human pentraxin 2 vs -31.8 m for those in the placebo group (difference, +31.3 m [90% CI, 17.4 to 45.1]; P < .001). The most common adverse events in the recombinant human pentraxin 2 vs placebo group were cough (18% vs 5%), fatigue (17% vs 10%), and nasopharyngitis (16% vs 23%). CONCLUSIONS AND RELEVANCE: In this preliminary study, recombinant human pentraxin 2 vs placebo resulted in a slower decline in lung function over 28 weeks for patients with idiopathic pulmonary fibrosis. Further research should more fully assess efficacy and safety. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02550873.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Raghu G, van den Blink B, Hamblin MJ, et al. Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial. JAMA. 2018. PMID: 29800034. doi:10.1001/jama.2018.6129

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。